Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pilot study to evaluate the safety, tolerability and efficacy of obeticholic acid (INT-747) for the treatment of portal hypertension

Trial Profile

A pilot study to evaluate the safety, tolerability and efficacy of obeticholic acid (INT-747) for the treatment of portal hypertension

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 26 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Obeticholic acid (Primary)
  • Indications Portal hypertension
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms PESTO
  • Sponsors Intercept Pharmaceuticals
  • Most Recent Events

    • 23 Jan 2014 New trial record
    • 09 Jan 2014 Results of this trial have been submitted for presentation at the International Liver Congress of the European Association for the Study of the Liver (EASL) in April 2014, according to an Intercept Pharmaceuticals media release.
    • 09 Jan 2014 Results from this trial support the initiation of a double-blind phase IIB trial of obeticholic acid in the treatment of portal hypertension, according to an Intercept Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top